⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study in Subjects With Light Chain (AL) Amyloidosis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study in Subjects With Light Chain (AL) Amyloidosis

Official Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)

Study ID: NCT03154047

Conditions

AL Amyloidosis

Interventions

NEOD001

Study Description

Brief Summary: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.

Detailed Description: Global, multicenter, Phase 2b, open-label extension study of subjects with AL amyloidosis who had a hematologic response to first-line treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant \[ASCT\]) and completed Study NEOD001-201. Subjects in this study may receive concomitant chemotherapy. Subject screening will occur during the 28 days prior to the first administration of study drug, which may overlap with the last visit in Study NEOD001-201. If all eligibility requirements are met, the subject will be enrolled and Screening assessments will be completed. Study visits will occur every 28 days based on scheduling from Month 1 Day 1. A ±5-day window is allowed for visits starting after Month 1. Subjects who discontinue study drug before the End of Study Visit (EOS) should have an Early Treatment Discontinuation Visit 30 (±5) days after their final administration of study drug. Each subject's study participation may be up to 38 months or until the study is terminated, whichever occurs first. The study consists of a Screening Phase (1 month), Treatment Phase (36 months), and EOS Visit (30 \[±5\] days after the last dose).

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

City of Hope, Duarte, California, United States

Colorado Blood Cancer Institute, Denver, Colorado, United States

Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States

University of Chicago Medicine, Chicago, Illinois, United States

Indiana University Simon Cancer Center, Indianapolis, Indiana, United States

Tufts Medical Center, Boston, Massachusetts, United States

Karmanos Cancer Institute, Detroit, Michigan, United States

Mayo Clinic - Minnesota, Rochester, Minnesota, United States

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Duke University Medical Center, Durham, North Carolina, United States

Cleveland Clinic, Cleveland, Ohio, United States

Oregon Health & Science University, Portland, Oregon, United States

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Vanderbilt University Medical Center, Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Westmead Hospital, Sydney, New South Wales, Australia

Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia

Medizinische Universität Wien, Vienna, , Austria

Hôpital Dupuytren - CHU Limoges, Limoges, , France

Hôpital Pitié-Salpêtrière, Paris, , France

Charité - Universitätsmedizin Berlin, Berlin, , Germany

University of Duisburg-Essen, Essen, , Germany

Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, , Germany

Universitätsklinikum Heidelberg, Heidelberg, , Germany

Alexandra General Hospital of Athens, Athens, , Greece

University Hospital of Patras, Patras, , Greece

Hadassah Medical Center (HMC), Jerusalem, , Israel

Fondazione IRCCS Policlinico San Matteo, Pavia, , Italy

Hospital Clínic de Barcelona, Barcelona, , Spain

Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, , Spain

Queen Elizabeth Hospital, Birmingham, England, United Kingdom

The Royal Free Hospital, London, England, United Kingdom

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: